Quirine C. Schornagel-Van Rossum
Hoofddorp, NH, Netherlands
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 11 publications
Author Correction: Early versus deferred use of CDK4/6 inhibitors in advanced breast cancer.
Journal: Nature
Published: July 22, 2025
Health-related quality of life with first- vs second-line CDK4/6 inhibitor use in advanced breast cancer: results from the SONIA trial.
Journal: Journal of the National Cancer Institute
Published: June 20, 2025
Health-related quality of life with first- vs second-line CDK4/6 inhibitor use in advanced breast cancer: results from the SONIA trial.
Journal: Journal of the National Cancer Institute
Published: June 20, 2025
Early versus deferred use of CDK4/6 inhibitors in advanced breast cancer.
Journal: Nature
Published: January 09, 2024
CBD-oil as a potential solution in case of severe tamoxifen-related side effects.
Journal: NPJ breast cancer
Published: February 06, 2023
Ritonavir-boosted antiretroviral therapy with paclitaxel: will it lead to boosted toxicity?
Journal: AIDS (London, England)
Published: December 22, 2021
Influence of probenecid on endoxifen systemic exposure in breast cancer patients on adjuvant tamoxifen treatment.
Journal: Therapeutic advances in medical oncology
Published: December 10, 2021
Therapeutic Drug Monitoring of Endoxifen for Tamoxifen Precision Dosing: Feasible in Patients with Hormone-Sensitive Breast Cancer.
Journal: Clinical pharmacokinetics
Published: September 19, 2021
Impact of Curcumin (with or without Piperine) on the Pharmacokinetics of Tamoxifen.
Journal: Cancers
Published: February 14, 2019
Showing 1-11 of 11
Last Updated: 09/26/2026